Analysts Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) PT at $45.60

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given an average rating of “Buy” by the five research firms that are presently covering the firm, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy recommendation. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $43.20.

A number of analysts have recently commented on the company. Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $54.00 to $42.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright boosted their price objective on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research note on Wednesday, February 26th. StockNews.com downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 14th. Royal Bank of Canada dropped their price objective on Karyopharm Therapeutics from $34.00 to $33.00 and set an “outperform” rating on the stock in a research note on Tuesday, May 13th. Finally, Barclays boosted their price objective on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 13th.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of KPTI. Velan Capital Investment Management LP bought a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $27,000. Focus Partners Wealth bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $31,000. TD Waterhouse Canada Inc. bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $32,000. Two Sigma Advisers LP boosted its stake in Karyopharm Therapeutics by 145.5% during the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares during the period. Finally, Opti Capital Management LP bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at approximately $85,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Stock Performance

Shares of KPTI stock opened at $5.13 on Tuesday. Karyopharm Therapeutics has a 1 year low of $3.51 and a 1 year high of $17.85. The stock has a fifty day moving average of $5.32 and a two-hundred day moving average of $8.61. The firm has a market capitalization of $44.32 million, a PE ratio of -5.03 and a beta of 0.33.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Monday, May 12th. The company reported ($2.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.21) by $1.44. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $35.12 million. Equities research analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).